What is Zacks Research’s Forecast for NKTR FY2024 Earnings?

Nektar Therapeutics (NASDAQ:NKTR) – Equities research analysts at Zacks Research increased their FY2024 earnings per share estimates for Nektar Therapeutics in a research note issued to investors on Monday, January 6th. Zacks Research analyst K. Das now forecasts that the biopharmaceutical company will earn ($0.76) per share for the year, up from their prior estimate of ($0.80). The consensus estimate for Nektar Therapeutics’ current full-year earnings is ($0.71) per share. Zacks Research also issued estimates for Nektar Therapeutics’ Q1 2025 earnings at ($0.22) EPS, Q2 2025 earnings at ($0.22) EPS, FY2025 earnings at ($0.87) EPS, Q1 2026 earnings at ($0.23) EPS, Q3 2026 earnings at ($0.21) EPS and FY2026 earnings at ($0.89) EPS.

Several other equities research analysts also recently weighed in on NKTR. B. Riley began coverage on Nektar Therapeutics in a research report on Wednesday. They set a “buy” rating and a $4.00 price target on the stock. BTIG Research reaffirmed a “buy” rating and set a $4.00 target price on shares of Nektar Therapeutics in a report on Monday, September 30th. HC Wainwright initiated coverage on shares of Nektar Therapeutics in a research report on Tuesday, December 10th. They issued a “buy” rating and a $6.50 price objective for the company. Finally, Piper Sandler started coverage on Nektar Therapeutics in a report on Monday, November 4th. They issued an “overweight” rating and a $7.00 price objective on the stock. Three research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $4.08.

Nektar Therapeutics Trading Down 4.2 %

Shares of NASDAQ NKTR opened at $1.14 on Thursday. The stock has a market cap of $210.28 million, a price-to-earnings ratio of -1.36 and a beta of 0.59. Nektar Therapeutics has a 12 month low of $0.48 and a 12 month high of $1.93. The company has a 50 day simple moving average of $1.09 and a two-hundred day simple moving average of $1.21.

Insider Buying and Selling

In other Nektar Therapeutics news, insider Jonathan Zalevsky sold 51,115 shares of the firm’s stock in a transaction on Thursday, December 19th. The stock was sold at an average price of $0.94, for a total transaction of $48,048.10. Following the completion of the sale, the insider now owns 326,904 shares of the company’s stock, valued at $307,289.76. This trade represents a 13.52 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Howard W. Robin sold 46,995 shares of the company’s stock in a transaction dated Tuesday, December 17th. The shares were sold at an average price of $1.01, for a total transaction of $47,464.95. Following the completion of the transaction, the chief executive officer now directly owns 1,195,710 shares in the company, valued at $1,207,667.10. The trade was a 3.78 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 155,575 shares of company stock worth $149,878. 3.71% of the stock is owned by corporate insiders.

Institutional Trading of Nektar Therapeutics

A number of large investors have recently made changes to their positions in the company. Samlyn Capital LLC purchased a new position in shares of Nektar Therapeutics in the 2nd quarter valued at $11,728,000. Eventide Asset Management LLC boosted its stake in shares of Nektar Therapeutics by 24.8% during the third quarter. Eventide Asset Management LLC now owns 9,400,000 shares of the biopharmaceutical company’s stock worth $12,220,000 after buying an additional 1,870,904 shares during the period. Millennium Management LLC grew its holdings in shares of Nektar Therapeutics by 56.1% during the second quarter. Millennium Management LLC now owns 4,659,469 shares of the biopharmaceutical company’s stock worth $5,778,000 after buying an additional 1,674,924 shares during the last quarter. Nantahala Capital Management LLC increased its position in Nektar Therapeutics by 66.0% in the 2nd quarter. Nantahala Capital Management LLC now owns 4,110,000 shares of the biopharmaceutical company’s stock valued at $5,096,000 after acquiring an additional 1,634,046 shares during the period. Finally, State Street Corp lifted its position in Nektar Therapeutics by 11.9% during the 3rd quarter. State Street Corp now owns 3,345,733 shares of the biopharmaceutical company’s stock worth $4,349,000 after acquiring an additional 355,759 shares during the period. 75.88% of the stock is currently owned by hedge funds and other institutional investors.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.